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Western blotting analysis
Protein samples extracted from left ventricles or cultured CFs were separated by 10% SDS-PAGE and transferred to polyvinylidene difluoride membrane as described previously [11] . Blots were probed with anti-PPARγ (Millipore-Upstate), anti-HDAC1(Santa Cruz), anti-mSin3A (Abcam), anti-pSmad3 (Cell Signaling Tech) and anti-GAPDH primary antibodies (Santa Cruz Biotech) and a horseradish peroxidaseconjugated secondary antibody, respectively. Bands were visualized by use of a Super Western Sensitivity Chemiluminescence Detection System (Pierce). Autoradiographs were quantitated by densitometry (NIH Image J).
Quantitative real-time RT-PCR analysis
Total RNA was extracted from CFs using TRIzol reagent (Invitrogen) and reverse transcribed to cDNA. cDNA was amplified by real-time quantitative PCR using the SYBR Green RT-PCR kit (Applied Biosystems) in an ABI PRISM 7500 sequence detection system (Applied Biosystems, Foster City, CA) with specific primers for mouse (PPARγ: 5'-GAT GGA AGA CCA CTC GCA TT-3' and 5'-AAC CAT TGG GTC AGC TCT TG-3'; or GAPDH: 5'-GTT GTC TCC TGC GAC TTC A-3' and 5'-GTG GTC CAG GGT TTC TTA CT-3') as described previously [11] . PPARγ mRNA levels were normalized using GAPDH mRNA and then standardized to the mRNA level of vehicle-treated CFs.
Statistical analysis
Results were expressed as mean ± SEM. Analyses were carried out the SPSS software version 11.0 for Windows (SPSS Inc., Chicago, Ill). Our primary statistical test was One-way or Two-way ANOVA. If ANOVA results were significant, a Bonferroni post hoc comparison, when appropriate, was performed. Paired samples were tested with a Student T test. A P value < 0.05 was considered statistically significant.
Results
Over-expression of Smad3 and Smad4 but not Smad2, enhances TGF-β1-induced inhibition of PPARγ promoter activity in CFs
Previously, we utilized a non-specific antibody against both Smad2 and Smad3 to confirm that these Smad proteins bind to the PPARγ promoter in response to TGF-β1 stimulation in mouse CFs using ChIP analysis. To further define which Smad protein is involved in TGF-β1-induced inhibition of PPARγ transcription, isolated CFs were transiently co-transfected with the various Smad plasmids with a Luc-hPPARγ promoter plasmid. After 24 h of transfection, CFs were treated with 4 ng/ml TGF-β1 for 12 h. The Dual-luciferase reporter assay showed that over-expression of Smad3 or Smad4 significantly enhanced TGF-β1-induced inhibition of PPARγ promoter activity (Fig. 1A,B) . In contrast, Smad2 overexpression did not affect PPARγ promoter activity in response to TGF-β1 (Fig. 1C) . Combined transfection of Smad3 and Smad4 further enhanced the suppression of PPARγ promoter activity by TGF-β1 compared with either Smad3 or Smad4 alone (Fig. 1D) . To further determine the role of Smad3 in mediating the inhibitory effect of TGF-β1 on PPARγ promoter activity, we transfected a dominant-negative form of the Smad3 plasmid. As shown in Fig 1E , over-expression of the mutant Smad3 significantly attenuated the inhibitory effect of TGF-β1. Consistently, transfection with lentivirus-encoding Smad3 shRNA, but not Smad2 shRNA, significantly attenuated TGF-β1-induced PPARγ mRNA down-regulation compared with the control shRNA (Fig 1F) . These results indicate that receptor-activated Smad3, but not Smad2, mediates TGF-β1-induced transcriptional suppression of PPARγ.
Location of Smad3 binding sites on the promoter of the PPARγ gene
To further elucidate the sites of SBEs on the promoter of the PPARγ gene, serial deletions of the PPARγ promoter reporter were constructed and transiently transfected into cultured CFs ( Fig. 2A) . Cells were treated with TGF-β1 for 12 h and the Dual-luciferase reporter assay was carried out. Compared with the full-length PPARγ gene promoter, deletion of the first 500bp fragment (A-2237) from -2737 to -2237 with respect to the transcription start site resulted in significantly decreased basal promoter activity, suggesting that transcriptional enhancers in the region played a role in maintenance of basal PPARγ gene promoter activity. The inhibitory effect of TGF-β1 on the truncated PPARγ gene promoter (i.e. A-2237) was preserved. Deletion of the region from -2237 to -1737 resulted in a significant increase in basal promoter activity of A-2237, and TGF-β1 treatment suppressed the transcriptional activity of the truncated promoter. In contrast, when the region from -1737 and -1237 was deleted (C-1237), basal transcriptional activity remained unchanged, but the inhibitory effect of TGF-β1 on promoter activity was abolished. Similarly, TGF-β1 treatment had no effect on the promoter activities of D-750 or E-500 (Fig. 2B) . Based on these results, two putative SBE sites (GTCT and AGAC) in the region from -1737 to -1237 with respect to the transcription start site were further examined by site-directed mutation methods. As shown in Fig. 2C , compared with their parent reporter B-1737, both the -1507 (AGAC→AtAt, -1507m) and -1524 mutations (GTCT→aTaT, -1524m) resulted in significant decreases in TGF-β1-induced inhibition of promoter activity. Further, the combination of -1507 and -1524 mutations (SBEm) led to complete loss of the TGF-β1-induced inhibitory effect. A schematic structure of the PPARγ gene is presented is Fig. 2D .
mSin3A binding to the promoter of the PPARγ gene in response to TGF-β1 stimulation in cultured CFs
To define which co-repressors are involved in TGF-β-induced PPARγ gene repression, we used ChIP assays to screen several common TGF-β signaling-related transcriptional corepressors, including Evi-1, mSin3A, TGIF, SNIP-1 and SIP-1. In cultured CFs, ChIP assays showed that in the absence of TGF-β1, moderate levels of Smad3 and low levels of HDAC1 and mSin3A were present at the PPARγ promoter. In contrast, SNIP-1, SIP-1, TGIF and Evi-1 did not bind to the PPARγ promoter in the presence of TGF-β1. However, TGF-β1 treatment enhanced the levels of Smad3 and the transcriptional co-repressors mSin3A and HDAC1 at the promoter region of the PPARγ gene compared with vehicle (Fig. 3 ).
Smad3-mSin3A-HDAC1 complex formation at the promoter of the PPARγ gene in response to TGF-β1
To further elucidate the molecular events at the PPARγ promoter, we used the DNAaffinity precipitation assay to examine the interaction among these molecules. Biotin-labeled oligomers consisting of SBE repeats were incubated with the protein extracts of untreated or TGF-β1 treated CFs. Low levels of phosphorylated smad3 bound to DNA in extracts of unstimulated cells, while TGF-β1 treatment enhanced Smad3 binding to the PPARγ promoter, and mSin3A and HDAC1 binding were also increased in the SBE probe-treated precipitants (Fig. 4) . There results provide evidence that activation of TGF-β1 signaling favors the formation of a transcription complex comprising Smad3, mSin3A and HDAC1 at the PPARγ promoter.
Silencing mSin3A and inhibiting HDAC1 attenuate TGF-β1-induced inhibition of PPARγ down-regulation
To further define the roles of mSin3A and HDAC1 in TGF-β1-induced inhibition of PPARγ gene transcription, isolated CFs were transfected with lentivirus-encoding shRNA against mouse mSin3A. Immunoblot assays showed that transfection of mSin3A shRNA dramatically decreased endogenous mSin3A expression compared with control shRNA. As expected, silencing mSin3A markedly attenuated TGF-β1-induced PPARγ down-regulation compared with the control shRNA (Fig. 5A-C) . Further, pretreatment with MS-275, a selective antagonist of HDAC1, significantly increased PPARγ expression in the presence of TGF-β1 compared with vehicle (Fig. 5D) .
Silencing mSin3A decreases TGF-β1-induced HDAC1 binding to the promoter of PPARγ
We have previously demonstrated that in the absence of TGF-β1, high levels of acetylated histone3 were present at the PPARγ promoter. While TGF-β1 treatment significantly increased binding of HDAC1, it decreased levels of acetylated histone3 at the PPARγ promoter in isolated CFs [11] . In CFs transfected with mSin3A shRNA, ChIP assays showed that silencing mSin3A expression completely prevented HDAC1 binding to the PPARγ promoter in the presence of TGF-β1 (Fig. 6) . These results suggest that, with the help of HDAC1, the PPARγ gene transcription was significantly inhibited in the presence of TGF-β1 and that mSin3A Fig. 3 . TGF-β1 treatment increased binding of the transcriptional repressor mSin3A to the PPARγ gene promoter in cultured CFs. CFs were treated with TGF-β1 (4 ng/ml) or vehicle for 1 h. Levels of SNIP1, SIP1, TGIF, Evi-1, Smad3, mSin3A and HDAC1 bound to the PPARγ promoter were determined by ChIP assay. A representative set of results from at least 3 independent assays is shown. * p<0.05 compared with respective vehicle control groups. Fig. 4 . TGF-β1 treatment enhanced the binding of pSmad3, mSin3A and HDAC1 to the PPARγ gene promoter in cultured CFs. CFs were treated with TGF-β1 (4 ng/ml) or vehicle for 1 h. Equal amounts of proteins were precleared with streptavidin-agarose beads and then incubated with 200 ng of biotinylated double-stranded 3×CAGA probe and streptavidin-agarose. The DNA-bound proteins were resolved by 7.5% SDS-PAGE and detected by immunoblotting with anti-pSmad3, anti-mSin3A and anti-HDAC1. Each experiment was repeated at least 3 times.
plays an essential role in HDAC1-mediated transcriptional inhibition of the PPARγ gene in response to TGF-β1.
Discussion
The current study has demonstrated that: 1) Smad3 acts as a key transcription factor to mediate TGF-β1-induced down-regulation of PPARγ in mouse CFs; 2) Two SBEs located at -1507 and -1524 with respect to the transcription start site are required for TGF-β1-induced transcriptional suppression of PPARγ; 3) Formation of the mSin3A-HDAC1-Smad3 complex on the promoter of PPARγ in response to TGF-β1 stimulation leads to transcriptional suppression of the PPARγ gene.
PPAR-γ has long been thought to function as a master regulator of glucose homeostasis and fat metabolism and is now emerging as a key regulatory molecule in fibrosis and vascular remodeling [16] [17] [18] [19] . Evidence is accumulating that, on one hand, there is a causal relationship between fibrosis and defective PPARγ expression and function and, on the other hand, pharmacological enhancement of PPARγ tissue levels and activity using PPARγ ligands or proteasomal inhibitors can effectively prevent, and perhaps even reverse, fibrosis and vascular remodeling [16] . For example, cardiomyocyte-specific PPARγ knockout mice have been shown to develop age-dependent cardiac hypertrophy [5] , and the decrease in myocardial PPARγ in these mice is associated with increasing severity of cardiac pathology in response to stress [20] .
Mice harboring a dominant-negative PPARγ mutation develop exaggerated cardiac fibrosis when challenged with angiotensin II [21] . We previously reported that disruption of TGF-β signaling by inducible over-expression of a dominant negative type II TGF-β receptor effectively prevented chronic pressure overload-induced down-regulation of myocardial PPARγ in mouse, whereas inhibition of PPARγ with T0070907 exacerbated and activation of PPARγ by rosiglitazone dramatically inhibited cardiac fibrosis in response to transverse aortic constriction [11] . Further, in isolated mouse CFs, TGF-β1 suppressed expression of PPARγ at the protein and mRNA levels.
However, the molecular events in the nucleus that underlie TGF-β-induced PPARγ transcriptional inhibition are poorly understood. Previous studies have shown that several families of transcription factors are responsible for the regulation of PPARγ transcription [22] . For example, constitutive expression of GATA-2 and GATA-3 can decrease PPARγ expression and thus inhibit adipocyte differentiation [23, 24] . Also, E2F4, when associated with p107 or p130, was implicated in repression of PPARγ expression during terminal adipocyte differentiation [25] . It remains unclear whether the canonical Smad2/3 pathway or a non-smad pathway orchestrates TGF-β-induced PPARγ transcriptional inhibition in mouse CFs.
It is clear that receptor activated Smad2 and Smad3 can bind to co-Smad, i.e. Smad4 to form a heteromeric complex and translocate into the nucleus to either promote or block target gene transcription. Although Smad3 and Smad2 share some structural characteristics, they clearly have important functional and structural differences [26, 27] . For example, the MH1 domains of Smad3 and Smad2 have different DNA binding ability and binding sites. In contrast to Smad2, which activates the TGF-β/activin response element, Smad3 elicits an antagonistic activity conferred by the MH1 domain. Here, we showed that transient overexpression of Smad3, but not Smad2, effectively enhanced the inhibitory effects of TGF-β1 on PPARγ promoter activity, providing further evidence for functional differences between Smad2 and Smad3. Labbe et al tested the effects of Smad2 and Smad3 on response elements of several gene promoters, including the goosecoid (gsc) promoters, the activin response element in the Mix.2 gene and 3TP-luc [28] . They found that Smad3 inhibited, and, Smad2 enhanced the activities of the first two response elements, but that Smad2 and Smad3 enhanced the activity of 3TP in a synergistic manner. These results demonstrate a genespecific effect of Smad3 and Smad2 on transcriptional regulation.
Our findings that both Smad3 and Smad4, but not Smad2, mediated TGF-β-induced PPARγ transcriptional inhibition in mouse CFs are consistent with a previous study in rat hepatic stellate cells [29] . Further, functional deletion promoter analysis showed that deletion in the region from -2737 to -2237 resulted in a dramatic decrease in basal promoter activity of the PPARγ gene. In contrast, deletion in the region from -2237 and -1737 caused a significant increase in promoter activity of the PPARγ gene. There results suggest that a key transcriptional enhancer and suppressor are located in the two regions. Future work is needed to identify these key transcriptional regulatory factors. Interestingly, we found that only the fragment between -1737 and -1237 played a critical role in TGF-β-induced transcriptional inhibition of PPARγ, since deletion of the region fully abolished the effect of TGF-β on the PPARγ promoter. Further, site-directed mutagenesis assays showed that two SBEs are located at -1507bp and -1524bp with respect to the transcriptional start site of the PPARγ gene.
Smad transcription complexes target specific genes for either induction or inhibition through the direct recruitment of transcriptional coactivators or corepressors to target promoters. Other modalities, including Smad interference with activators or repressors, and Smad cooperation with DNA, play a role in target gene regulation [30] . For example, activated Smad2/3-Smad4 complexes achieve high affinity and selectivity for target gene promoters by associating with diverse DNA-binding factors. Therefore, in most cases the Smad-interacting transcriptional co-factors and DNA-binding partners play important roles in the specific transcriptional effects (i.e activation or repression) that are exerted on a target gene.
Several Smad2, 3 transcriptional co-repressors and DNA-binding partners have been identified, including TGIF, Evi-1, SIP-1, c-Ski and mSin3 [31, 32] . For example, TGIF interacts specifically with Smad2 and Smad3 and recruits a complex of general corepressors such as C-terminal-binding protein 1(CtBP) [33] . Further, binding of TGIF prevents the interaction of Smads with co coactivators to repress the activation of target gene expression. The protooncoprotein Ski and the related protein SnoN act as the co-repressors of Smad3, where Ski prevents the formation of an activated Smad2,3 complex [34] and competes with p300 for binding to Smad3 on the target gene promoter [35] , and finally antagonizes the growth inhibitory response of epithelial cells to TGF-β [36] . Evi-1, a zinc finger containing protooncoprotein, was shown to bind to Smad3 and corepressor protein CtBP and inhibit Smad3 binding to DNA, thus exerting full repression of the TGF-β response [37] .
Chromatin plays an important role in the regulation of gene transcription, replication and recombination by controlling the access of regulatory proteins to the DNA [38] . Acetylation of core histones relaxes the nucleosome and permits transcription factors and coactivators to gain access to recognition elements and initiate transcription. Corepressors mediate transcriptional suppression through binding with HDACs, which deacetylate core histones and generate a restrictive chromatin environment to prevent the transcription machinery from binding to the promoter DNA [39] . To determine which co-repressor was involved in HDAC1-related transcriptional inhibition of PPARγ in the presence of TGF-β1, we screened the potential transcriptional co-repressors using ChIP analysis. We observed that, in response to TGF-β1, HDAC1 and mSin3A binding to the PPARγ promoter was significantly increased. The DNA-affinity precipitation assay also showed that TGF-β1 treatment potentiated mSin3A and HDAC1 binding to PPARγ-SBE probe-labled cellular precipitants. Similarly, a previous study showed that p53 anchoring of activated Smads and mSin3A to the AFP promoter plays a critical role in TGF-β-induced transcriptional repression in hepatic cells [40] . Together, these results suggest that TGF-β1-induced inhibition of PPARγ transcription depends on formation of a functional transcription complex at the PPARγ promoter that includes Smad3, mSin3A and HDAC1.
In mammals, Sin3 exists as two subtypes, mSin3A and mSin3B, that share a similar scaffolding function for the assembly of the corepressor complex [41] . Previous studies demonstrated that the Sin3 corepressor complex serves as an HDAC-associated coregulator complex in negatively regulating promoter-dependent transcription, and is also implicated in the regulation of DNA and histone methylation, nucleosome remodeling, and N-acetylglucosamine transferase activity [42] . HDACs have been shown to be recruited directly by Smads or by associated co-repressors on the target gene promoter [43] . Since Sin3 functions as a master scaffold to provide a platform for the assembly of transcriptional machinery [44] , Sin3-mediated gene silencing is thought to be achieved primarily through scaffolding of core HDAC complexes [45] . Consistent with this concept, we found that knockdown of the mSin3A gene fully prevented TGF-β1-induced HDAC1 binding to the PPARγ promoter, and that inhibition of HDAC1 with the specific blocker MS-275 also attenuated TGF-β1-induced down-regulation of PPARγ mRNA expression. Further, it has been shown that pharmacological inhibition of HDAC1 is associated with improvement in cardiac function via a direct anti-fibrotic effect in rats with heart failure [46] . We did not detect mSin3B binding to the PPARγ promoter in response to TGF-β1 by ChIP analysis (unpublished data), suggesting that mSin3B is not likely to be involved in mediating TGF-β1-induced down-regulation of PPARγ in CFs. Collectively, our results suggest that mSin3A plays an essential role in HDAC1-mediated transcriptional inactivation of the PPARγ gene in response to TGF-β1.
